Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RPT-2950
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Johnson & Johnson
Deal Size : $149.0 million
Deal Type : Series B Financing
Details : ROME intends to use the funds to advance its drug candidate, RPT-2950, an inhibitor of LINE-1 reverse transcriptase (RT), through early clinical trials, including Phase 1 studies to evaluate safety and determine optimal dose, and further advancement of p...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 09, 2023
Lead Product(s) : RPT-2950
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Johnson & Johnson
Deal Size : $149.0 million
Deal Type : Series B Financing
Details : ROME’s mission is to harness the power of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats – to discover powerful new classes of medicines for cancer and autoimmune diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 14, 2021
Rome Therapeutics debuts with $50M and Rosana Kapeller as CEO
Details : The capital would help in clinical advancement of several promising drug targets identified by ROME and may boost launch of multiple discovery programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 27, 2020